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Histone deacetylase inhibitors (HDIs) are under investigation for the treatment of a
number of human health problems. HDIs have proven therapeutic value in refractory
cases of cutaneous T-cell lymphoma. Electrocardiographic ST segment morphological
changes associated with HDIs were observed during development. Because ST segment
morphology is typically linked to changes in ATP sensitive potassium (KATP) channel
activity, we tested the hypothesis that HDIs affect cardiac KATP channel subunit
expression. Two different HDIs, romidepsin and trichostatin A, caused ∼20-fold increase
in SUR2 (Abcc9) subunit mRNA expression in HL-1 cardiomyocytes. The effect was
specific for the SUR2 subunit as neither compound causes a marked change in SUR1
(Abcc8) expression. Moreover, the effect was cell specific as neither HDI markedly altered
KATP subunit expression in MIN6 pancreatic β-cells. We observe significant enrichment
of the H3K9Ac histone mark specifically at the SUR2 promoter consistent with the
conclusion that chromatin remodeling at this locus plays a role in increasing SUR2 gene
expression. Unexpectedly, however, we also discovered that HDI-dependent depletion
of cellular cholesterol is required for the observed effects on SUR2 expression. Taken
together, the data in the present study demonstrate that KATP subunit expression can be
epigenetically regulated in cardiomyocytes, defines a role for cholesterol homeostasis in
mediating epigenetic regulation and suggests a potential molecular basis for the cardiac
effects of the HDIs.
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Introduction
Histone deacetylase inhibitors (HDIs) have emerged as potential therapeutic agents for
the treatment of cancer and heart disease (Ma et al., 2009; McKinsey, 2012). Histone
deacetylases (HDACs) are known to be key co-factors of the machinery that regulates gene
transcription. HDACs typically work in concert with DNA binding proteins to remove covalently
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attached acetyl groups from lysine residues contained within
histone proteins, resulting in less accessible chromatin and
reduced gene transcription (Kouzarides, 2007), however, this
simple model of HDI action may belie the diverse effects of
HDIs that can affect both normal and cancerous cell viability
(Falkenberg and Johnstone, 2014).
To date, four HDIs—romidepsin, vorinostat, belinostat, and
panobinostat—have been approved by the FDA for treating
heamatologic malignancies including refractory cutaneous T-cell
lymphoma or multiple myeloma (Mann et al., 2007; Piekarz
et al., 2011; Coiffier et al., 2012; Lee et al., 2015; Richardson
et al., 2015). While HDIs have proven successful, cardiac safety
has been a concern. Non-specific ST segment changes, long QT,
atrial fibrillation, and torsades de pointes have all been reported
in clinical trials (Sandor et al., 2002; Shah et al., 2006; Stadler
et al., 2006; Steele et al., 2008; Lynch et al., 2012; Noonan et al.,
2013). In a recent trial with romidepsin, the most common ECG
finding was ST segment morphological changes with no evidence
of associated myocardial ischemia (Noonan et al., 2013). ST
segment elevation and depression are typically associated with
the activation of ATP-sensitive (KATP) channels during ischemia
(Kubota et al., 1993; Li et al., 2000), suggesting that HDIs may
specifically affect KATP channel subunit expression in cardiac
myocytes.
HDIs have also shown promise in the treatment of
cardiovascular disease (McKinsey, 2012). Trichostatin A (TSA)
interferes with phenylephrine-induced hypertrophy of neonatal
ventricular myocytes (Cao et al., 2011) and studies in animal
models have shown that HDIs inhibit the development of cardiac
hypertrophy due to angiotensin II infusion, aortic banding or
pressure overload (Kee et al., 2006; Kong et al., 2006). HDIs have
also been shown to inhibit the expression of hypertrophic genes,
inflammatory markers, and fibrosis in the diseased heart (Liu
et al., 2008; Cardinale et al., 2010; Cao et al., 2011). Interestingly,
HDIs have also been shown to reduce infarct size and maintain
contractile function following ischemia-reperfusion, similar to
the effects of pharmacological or ischemic preconditioning
(Zhao et al., 2007; Xie et al., 2014), which again is associated
with activation of sarcolemmal KATP channels (Suzuki et al.,
2002).
Based on these observations, we hypothesized that HDIs
may specifically affect the expression of KATP channel subunits.
A single KATP channel is a hetero-octomeric protein complex
comprised of four pore-forming, inward rectifier (Kir6.1 or
Kir6.2) and four sulfonylurea receptor (SUR1 or SUR2) subunits
that are encoded by four separate genes (Inagaki et al., 1995a,b,
1996; Chutkow et al., 1999). Specific subunit combinations
make up KATP channels in different tissues. For example, KATP
channels in mouse atrial cardiomyocytes and pancreatic β-
cells are composed of SUR1 and Kir6.2, while SUR2A and
Kir6.2 form KATP in ventricular myocytes (Inagaki et al., 1995b,
1996; Flagg et al., 2008). There are relatively few studies to
identify factors that regulate KATP channel subunit expression
and many of these have been focused on pancreatic β-cell
models rather than cardiomyocytes (Ashfield and Ashcroft, 1998;
Hernandez-Sanchez et al., 1999; Kim et al., 2002). One study
focused on myocardium demonstrated an important role for
forkhead transcription factors in regulating KATP expression
(Philip-Couderc et al., 2008), and we recently showed that
DNA methylation can modulate SUR2 expression suggesting
that epigenetic mechanisms may also regulate KATP subunit
expression (Fatima et al., 2012). There have been no previous
studies examining the effects of HDACs or HDIs on KATP subunit
expression.
The results show that HDIs cause a specific increase
in SUR2 expression in HL-1 cardiomyocytes but have no
effect on MIN6 pancreatic β-cells indicating that HDIs have
tissue specific mechanisms of action. Moreover, while HDAC-
dependent histone acetylation likely contributes to the regulation
of KATP expression, we made the unexpected discovery that TSA-
dependent depletion of cholesterol was required for changes in
SUR2 expression. Taken together the data demonstrate that HDIs
specifically affect transcription of sarcolemmal KATP channel
subunits and define a novel cholesterol-dependent mechanism
that links HDIs with KATP subunit expression.
Materials and Methods
Cell Culture
Atrial myocyte derived HL-1 cell cultures were maintained in
Claycomb medium (Sigma) (Claycomb et al., 1998). Cells were
plated in tissue culture flasks coated overnight with gelatin
(0.02% w/v) and fibronectin (0.5% v/v). MIN6 cells were
maintained in DMEM containing 10% fetal bovine serum and
100µg/mL penicillin/streptomycin. In all experiments to inhibit
histone deacetylase (HDAC) activity, cells were incubated in
standard culture medium supplemented with Trichostatin A
(TSA) or Romidepsin at concentrations given in the text for 72 h.
In some experiments, culture medium was also supplemented
with cholesterol (250X cholesterol lipid concentrate, Gibco).
Culture medium was changed daily.
Quantitative RT-PCR
Relative expression of KATP channel subunit mRNA was
examined using quantitative RT-PCR, as described previously
(Fatima et al., 2012). Total RNA was isolated using a silica-based
column protocol (Qiagen, RNeasy) following the manufacturer’s
protocols. Isolated RNA was then treated with DNAseI to
digest residual genomic DNA and repurified using a silica-
based column protocol. RNA concentration was determined
spectrophotometrically (Nanodrop Technologies, Inc). cDNA
was synthesized from 1µg RNA (Superscript III, Invitrogen).
PCR was carried out using a CFX384 Real Time PCR Detection
System (Bio-Rad, Inc.), using Taqman© probe and primer pairs
(Applied Biosystems, Inc.) for monitoring reaction progress.
Twenty nano gram of template cDNA was used in all reactions.
Reactions with each primer/probe pair and template were
performed in triplicate. Relative mRNA expression (compared
to Hprt) is reported as 2−1Ct ∗ 1000 for untreated HL-1 and
MIN6 cells. The fold change in expression in response to drug
treatment is reported as 2−11Ct, where 11Ct = 1Ct (drug) −
1Ct (notreatment).
Protein Isolation and Western Analysis
Cells were washed with PBS and disrupted with RIPA lysis buffer
(Santa Cruz) supplemented with protease inhibitors (Roche).
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Protein concentration was determined by the BCA method
(Pierce). For Western analysis, proteins (typically 50µg) were
separated by PAGE and transferred to PVDF membrane. Signal
was visualized with the SuperSignal West Dura ECL substrate
(Pierce).
Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) assay was performed
using the SimpleChip enzymatic chromatin IP kit (Cell
Signaling Technology) according to manufacturer’s protocol.
Briefly, 1 × 108 cells were incubated with 1% formaldehyde
in 1X PBS for 10min at room temperature followed by
quenching with 0.125M glycine for 5min. After cell lysis,
cross-linked chromatin was digested with micrococcal nuclease,
followed by sonication to yield fragments of 200–1000 bp.
Soluble chromatin fragments were incubated with antibodies
against AcH3 (Abcam, ab-10812), control IgG (Cell Signaling
Technology, 2729) and H3 (Cell Signaling Technology, 4620).
Bound chromatin was precipitated using MagnaChip protein
A+G magnetic beads (Millipore). Precipitated complexes were
eluted, decrosslinked and purified. Purified DNA was amplified
by qPCR with primer set corresponding to the promoter
regions (−1 kB) for SUR1 and SUR2 (Qaigen). The data was
analyzed according to comparative Ct method, normalized to
IgG control and reported as fold change in binding relative to
control.
Genome-wide Expression Analysis
MouseRef-8 v2.0 Expression BeadChips (Illumina Inc., San
Diego, CA, USA) were used to measure relative levels of
mRNA expression for 24,854 well-established annotated
coding transcripts. Preparation of labeled cDNA, hybridization,
imaging, and data collection were carried out at the Cleveland
Clinic Genome Core Facility. Background subtracted,
quantile normalized data were generated and analyzed
using GenomeStudio (Illumina Inc., San Diego, CA, USA),
GenePattern 2.0 (Broad Institute, Cambridge, MA, USA)
and GATHER (Chang and Nevins, 2006) software packages.
Four paired samples (treated and control) of each group
were tested. Cells were treated with either TSA (30mg/mL)
or Romidepsin (5 nM). Differentially expressed transcripts
were filtered using strict criteria for, accurate detection in
at least three out of four samples, transcripts with 4-fold
expression level differences and were regulated by both TSA and
Romidepsin.
Cholesterol Labeling with Filipin
The protocols were adapted from the protocols of Leventhal
et al. (2001). After treatment for 72 h with TSA or TSA
combined with cholesterol, HL-1 and MIN6 cells were
fixed in formalin for 10min at room temperature. Fixed
cells were labeled with filipin (0.05mg/mL in PBS, Sigma)
and PicoGreen (1:1000, Molecular Probes) for 1 h at
room temperature to label non-esterified cholesterol and
DNA, respectively. Images were obtained using a Leica
AF6000 using the same exposure between samples within an
experiment.
Results
HDIs Increase SUR2 Subunit Expression in HL-1
Cardiomyocytes but not MIN6 Pancreatic β-cells
The objective of the present study was to test the hypothesis
that histone deacetylase inhibitors (HDIs) cause changes in KATP
channel subunit expression. For these studies, we made use of
two cell lines that express KATP channel subunits—HL-1 atrial
cardiomyocytes and MIN6 pancreatic β-cells. Figure 1 shows the
distribution of SUR1 and SUR2 in HL-1 cells. Expression of SUR
1 is greater than SUR2 in both HL-1 and MIN6 cells, consistent
with the distribution of subunits in primary tissue (Inagaki et al.,
1995b, 1996; Flagg et al., 2008). In this study, we compared
the responses of these two cell types to determine 1) if HDIs
modulate KATP expression and 2) if the effects are tissue specific.
Figure 2 shows the effects of HDAC inhibition on SUR1 and
SUR2 mRNA expression in HL-1 cardiomyocytes. Treatment
for 72 h with trichostatin A (TSA) induced a concentration-
dependent increase in SUR2 mRNA expression with little or no
change in SUR1. In contrast to the results with HL-1 cells, neither
SUR1 nor SUR2 mRNA expression was markedly altered by
HDAC inhibition in MIN6 pancreatic β-cells (Figure 2B). Taken
together, these data demonstrate that HDIs do modulate KATP
subunit expression and that this occurs in a cell or tissue specific
manner.
Expression of SUR2 Correlates with Histone
Acetylation at the Promoter
To begin to elucidate the mechanism underlying the TSA-
dependent increase in SUR2 expression, we confirmed that
the HDAC inhibitors induced a global increase in histone
acetylation in HL-1 cells. As expected, treatment with TSA
significantly increased the amount of acetylated histone H3 and
H4 without changes in the total histone protein (Figure 3A).
Moreover, the increase in histone acetylation is concentration
dependent and mirrors the concentration dependence of changes
in SUR2 expression, suggesting that HDIs are influencing SUR2
expression through epigenetic histone modification. TSA also
FIGURE 1 | SUR1 and SUR2 expression in HL-1 and MIN6 cell lines.
Relative mRNA expression of SUR1 and SUR2 obtained in atrial
myocyte-derived HL-1 (n = 13) and pancreatic β-cell-derived MIN6 cells
(n = 5). Expression (normalized to Hprt) was assessed by quantitative RT-PCR.
Gene-specific Taqman primer and probes were obtained from Applied
Biosystems. SUR1 expression was markedly higher in both cell lines when
compared to SUR2.
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FIGURE 2 | HDAC inhibitors (HDIs) significantly increase SUR2
expression in HL-1 cells but not MIN6 cells. (A) HDAC inhibition with
trichostatin A (TSA) caused a marked, dose-dependent, increase in SUR2
expression, while SUR1 expression is essentially unchanged (n = 3–10). (B)
Like TSA (30 ng/mL), another HDI, romidepsin (5 nM), caused an increase in
SUR2 expression in HL-1 cardiomyocytes with little change in SUR1. In
contrast, neither TSA nor romidepsin affected SUR subunit expression in MIN6
pancreatic β-cells (n = 5).
induces a similar increase in histone acetylation in MIN6 cells
(Figure 3B). We examined the effects of TSA on gene specific
histone acetylation using chromatin immunoprecipitation
(ChIP). These results (Figure 3C) demonstrate a significant
enrichment of the H3K9Ac histone mark at the SUR2, but
not SUR1, promoter. Taken together, these data indicate that
HDAC activity at the SUR2 promoter normally suppresses SUR2
transcription in HL-1 cardiomyocytes and that inhibition of this
activity causes a specific increase in SUR2 expression.
Genome-wide Expression Analysis Reveals
Potential Role for Cholesterol Homeostasis
To gain further mechanistic insight, we next performed a
comprehensive genome-wide expression BeadArray profiling to
determine the transcripts that are up- and down-regulated by
HDIs in HL-1 cells (Figure 4). Three hundred fifty five genes
were found to be increased or decreased more than 4-fold in
the presence of TSA. Similarly, 415 genes were changed more
than 4-fold by romidepsin with 171 genes common to the two
FIGURE 3 | Changes in SUR2 expression correlate with increased
histone acetylation at the promoter. (A) Representative western blot
demonstrating the concentration-dependent increase in histone acetylation
induced by TSA (30 ng/mL). A significant increase in both H3K9ac and
H4K8ac activating histone marks, with no change in total histone protein, was
observed. The concentration dependence of the TSA-dependent increase in
SUR2 expression appears to correlate with the increase in histone acetylation.
(B) Representative western blot showing that exposure of MIN6 cells to TSA
causes a similar increase in histone acetylation. (C) Summary data from
chromatin immunoprecipitation (ChIP) experiments demonstrating that the
activating histone mark H3K9ac is enriched at the SUR2, but not SUR1,
promoter following TSA treatment. *p < 0.05.
data sets. Analysis of the data set using the GATHER software
(Chang and Nevins, 2006) revealed marked changes in genes
associated with muscle contraction (GO: 0006936), including
Myh6, Ttn, Casq2, Tnni3, Acta1, Nppb, and Tnni2. qRT-PCR
analysis confirmed at least 4-fold differential expression in five
of the seven transcripts that we tested (Figure 4C). One of these
transcripts (Tnni2) was expressed at very low levels and the
other (Ttn) was only decreeased 2.8-fold. We also annotated the
171 common gene dataset for enrichment of transcription factor
binding sites (TRANSFAC v 8.2). Interestingly, this analysis
demonstrated significant enrichment for sterol response element
binding proteins (SREBPs) activity in response to HDIs. (60 of
171 transcripts, p < 0.0001). The enrichment of SREBP binding
sites in the subset of transcripts affected by HDIs suggests that
SREBP may play a role in mediating the effects of HDIs on
KATP channel subunit expression. This possibility was wholly
unexpected, however, it should be pointed out that a previous
study noted the presence of SREBP binding sites in the promoter
regions of the SUR2 and Kir6.2 genes (Philip-Couderc et al.,
2008), and therefore we followed up this lead.
HDIs Specifically Deplete HL-1 Cells of
Cholesterol
A major physiological regulator of SREBP activity is cellular
cholesterol. Reduced cholesterol levels in the endoplasmic
reticulum trigger a sequence of events leading to cleavage of
full length SREBP, allowing translocation of the transcriptionally
active SREBP cleavage product to the nucleus (Jeon and
Osborne, 2012). Interestingly, recent evidence suggests that
HDIs can interfere with cholesterol homeostasis (Meaney, 2014).
Therefore, we investigated the effects of TSA treatment on
cellular cholesterol in HL-1 and MIN6 cells cells using filipin,
a fluorescent antibiotic that has been used as a qualitative
Frontiers in Pharmacology | www.frontiersin.org 4 August 2015 | Volume 6 | Article 168
Fatima et al. HDIs, cholesterol and KATP expression
FIGURE 4 | BeadArray profiling reveals a potential role for cholesterol
and SREBP. (A) Venn diagram illustrating the number of genes specifically
changed (≥4-fold increase or decrease). Analysis using GATHER software
(Chang and Nevins, 2006) focused on the common gene set that was altered
by both compounds. (B) Shown are the BeadArray signal intensities of seven
transcripts that are included in the top gene ontology hit (GO0006936: muscle
contraction). (C) Expression changes were confirmed in 5 of 7 genes tested by
qRT-PCR. (D) Annotation of common gene set for transcription factor binding
sites (TRANSFAC, v8.2) revealed a putative role for SREBP in 60 out of 171
genes annotated.
measure of cellular cholesterol (Bittman and Fischkoff, 1972).
TSA exposure markedly decreased filipin staining in HL-1 cells
and cholesterol but did not affect filipin staining in MIN6 cells
(Figure 5) suggesting that TSA-dependent cholesterol depletion
might be required for TSA effects on gene expression.
Cholesterol Suppresses the Effects of HDIs on
KATP Subunit Expression
To determine whether TSA-dependent disruption of cholesterol
homeostasis mediates the effects on KATP expression, we assessed
SUR2 expression in HL-1 cells incubated in culture medium
supplemented with increasing concentrations of cholesterol and
a constant concentration of TSA. Addition of cholesterol to
the media completely restored cellular cholesterol as evidenced
FIGURE 5 | TSA depletes cholesterol in HL-1 cells, but not MIN6 cells.
(A) Representative images of HL-1 or MIN6 cells labeled with filipin
(Cholesterol, blue) and picoGreen (Nuclei, green). (B) Treatment with TSA
(30 ng/mL) markedly reduces filipin staining in HL-1 cells but has little effect on
filipin staining in MIN6 cells. Scale bar = 25µm.
by the restoration of filipin staining (Figure 6A). Cholesterol
also abolished the effects of TSA on gene expression in
a concentration-dependent manner (Figure 6B). Importantly,
TSA continued to inhibit HDAC activity as evidenced by
the increase in acetylated H3 in the presence or absence of
cholesterol. Taken together, this data indicates that cholesterol
depletion is required for HDI-dependent effects on KATP subunit
expression in HL-1 cardiomyocytes.
Discussion
The data in the present study demonstrate two novel aspects
regarding the transcriptional control of KATP channel subunits.
First, we show that inhibiting HDAC activity specifically
increases SUR2 gene transcription in HL-1 cardiomyocytes. This
result implies that under normal circumstances HDACs are
recruited to the SUR2 gene locus in HL-1 cells contributing
to the suppression of SUR2 expression in these cells under
basal conditions. Second, we show that disruption of cellular
cholesterol homeostasis is a critical mediator of HDI effects in
HL-1 cells. This result implies that cholesterol homeostasis, in
general, may be an important determinant of KATP expression in
the cardiovascular system.
Specific Epigenetic Regulation of KATP Channel
Subunit Expression by HDACs
Covalent histone modifications including acetylation,
methylation, ubiquitylation, sumoylation, and phosphorylation
are increasingly recognized as epigenetic regulators of when
and where genes are actively expressed (Kouzarides, 2007). By
promoting a more compact chromatin conformation, histone
deacetylation is an important gene silencing factor. Here we show
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FIGURE 6 | Cholesterol abolishes the effect of TSA. (A) Representative
images of HL-1 cells treated with TSA alone or TSA + 1X cholesterol. Inclusion
of cholesterol in the media prevents the marked reduction in cellular
cholesterol caused by TSA. Scale bar = 25µm. (B) Summary data from
experiments (n = 5) in which HL-1 cells were treated with a constant
concentration of TSA (30 ng/mL) together with increasing amounts of
cholesterol. Importantly, cholesterol did not prevent the increase in histone
acetylation (inset) indicating that cholesterol did not interfere with TSA access
to the cell or enzymatic activity.
that inhibiting HDAC activity increases SUR2 gene transcription
in HL-1 cardiomyocytes. This is the first demonstration that
HDIs can influence KATP channel subunit expression providing
evidence that KATP channel subunit expression is normally
determined in part by HDAC-dependent epigenetic regulation.
Specificity is a key feature of epigenetic regulation of KATP
channel expression. First, HDIs exhibit cell specific effects as
evidenced by the observation that KATP subunit expression is
markedly affected in HL-1 cardiomyocytes but unaffected in
MIN6 cells. HL-1 cells appear to be primed to express SUR2,
but tonic suppression by HDACs normally maintains a low level
of SUR2 expression. In contrast, the appropriate transcriptional
activators of SUR2 expression appear to be absent in MIN6
cells and in this case suppression of SUR2 gene expression by
HDACs would be redundant and is therefore not present. In
addition to cell specificity, epigenetic regulation of KATP channel
expression is also subunit specific. HDIs specifically increase
histone acetylation at the SUR2 gene but have no effect at
the SUR1 locus. This demonstrates that HDACs are recruited
specifically to the SUR2 locus in order to establish the pattern of
KATP subunit expression observed in HL-1 cells.
HDI Therapy, Epigenetics, and Arrhythmia
Disruption of the appropriate KATP channel composition or
function has been shown to cause arrhythmias or abnormal ECG
responses to ischemia. Using transgenic models that overexpress
KATP subunits, we have shown that disrupting normal KATP
composition by overexpressing SUR1 is arrhythmogenic (Flagg
et al., 2007), illustrating the importance of establishing the
appropriate channel composition in the mouse heart (Flagg et al.,
2008; Glukhov et al., 2010). Genetic or pharmacologic inhibition
of KATP, for example, completely abolishes the ST segment
elevation associated with ischemia (Kubota et al., 1993; Li et al.,
2000) and KATP channel openers such as pinacidil have been
shown to induce ST segment elevation independent of ischemia
(Yan and Antzelevitch, 1999). KATP is a particularly potent means
of modulating cardiac action potential duration. Activation of
just 1% of the total KATP channels available has been shown to
shorten the APD by 50% (Nichols et al., 1991; Weiss et al., 1992;
Knopp et al., 1999). Moreover, in ischemia models it has been
shown that shortening of APD by only about 20% is correlated
with marked ST elevation of about 5–10mV (Kingaby et al.,
1986). Based on these observations, it is possible that even very
small changes in KATP could be manifest as changes in the ECG.
The onset of cardiac arrhythmias has been observed in
several clinical and pre-clinical studies of HDI therapy (Berry
et al., 2008). Ventricular tachycardia, torsades de pointes, and
atrial fibrillation have been reported as rare cardiovascular
events in early phase trials of HDIs (Sandor et al., 2002;
Kelly et al., 2005; Piekarz et al., 2006; Lynch et al., 2012).
The major cardiac effect associated with romidepsin therapy is
asymptomatic, non-specific, ischemia-independent ST segment
elevation or depression (Sandor et al., 2002; Piekarz et al., 2006;
Noonan et al., 2013). Because ST segment elevation is typically
associated with activation of KATP channels (Kubota et al., 1993;
Li et al., 2000), the cardio-specific effects of romidepsin and
TSA on KATP channel subunit expression provide a potential
molecular basis for the cardiac effects associated with HDIs.
Similarly, re-entrant arrhythmias can be promoted by activation
of KATP (Billman, 2008). Other mechanisms such as decreased
connexin 43 expression (Xu et al., 2013) or non-specific HERG
blockade have been suggested to account for the cardiac effects
of HDI therapy. Here we suggest that epigenetic alterations in
cardiac KATP channel expression may also contribute to the
electrophysiological events observed during HDI-therapy.
HDIs, Cholesterol, and KATP Expression
The second major finding in this study is the discovery of a key
role for cholesterol depletion in mediating the effect of HDIs
on SUR2 expression. The key clue that focused attention on
cholesterol was the association of SREBP with the gene changes
induced by the HDIs (Figure 4). SREBPs are transcription factors
that are typically associated with cellular lipid homeostasis
(Jeon and Osborne, 2012). Previous studies have linked HDIs
with a reduction of cholesterol. For example, Niemann-Pick C
disease causes intracellular cholesterol accumulation as a result
of mutations in the NPC1 or NPC2 gene product that are
critical for cholesterol trafficking [Ory, 2004 and HDIs have
been shown to largely correct the cholesterol accumulation
phenotype both in fibroblasts cultured from humanNPC patients
(Pipalia et al., 2011) and neural stem cells from NPC−−/−−
mice (Kim et al., 2007). Similarly, others have shown that
TSA causes a significant reduction in cellular cholesterol by
increasing expression of genes that traffic and export cholesterol
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as well as inhibiting expression of genes in the mevalonate
pathway of cholesterol synthesis (Nunes et al., 2013). The specific
molecular mechanisms driving cholesterol reduction in HL-1
cells in the present study remain to be determined as does the
cell-specific basis for the HDI effects on cholesterol homeostasis.
Nevertheless, it is clear that HDIs significantly disrupt cellular
lipid homeostasis in HL-1 cardiomyocytes, but not MIN6
pancreatic β-cells.
The data indicate that maintaining cellular cholesterol
prevents the effect of HDIs on KATP subunit expression. This
finding suggests the very intriguing conclusion that there
is a link between cellular cholesterol homeostasis and KATP
expression. There have been no previous studies that directly
link cholesterol homeostasis with KATP channel expression. In
silico analysis previously identified SREBP binding sites in the
SUR2 and Kir6.2 promoters (Philip-Couderc et al., 2008), but
the functional relevance of those putative binding sites has not
specifically been explored. Interestingly, there have been studies
that indirectly link cholesterol homeostasis with KATP expression.
Hypercholesterolemia, which is expected to inhibit SREBP,
has been associated with impaired ischemic preconditioning
(Csonka et al., 2014) which requires functional sarcolemmal
KATP channels (Suzuki et al., 2002). It should also be noted
that there is a precedent for lipid homeostasis and SREBP in
regulating the expression of an inward rectifying potassium
channel. Park and colleagues demonstrated that lipid lowering
leads to an increase in GIRK1 expression through activation
of SREBP-1 (Park et al., 2008). The present results suggest
that cholesterol homeostasis and lipid metabolism in general
may have analogous effects on KATP subunit expression with
consequent arrhythmias.
Conclusion
In summary, the results presented in this study demonstrate
that HDIs such as TSA and romidepsin cause marked changes
in the expression of KATP channel subunits. This defines a
role for HDACs in determining which KATP channel subunits
are expressed in cardiomyocytes but not pancreatic β-cells.
Moreover, the data demonstrate a key role for cholesterol
homeostasis in regulating this process. Taken together, these
novel observations could lead to new strategies to modulate
sarcolemmal KATP channel structure and function in the heart
where it protects against stress and ischemia (Flagg et al.,
2010). Moreover, our observations may explain the ST segment
morphological changes that are associated with HDI therapy in
cancer patients.
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